跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
DDC-3
首页
药物
DDC-3
DDC-3
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Treatment of prostate cancer with DDC inhibitor
US 8324280 B2
申请人: WAFA LATIF
优先权: 2009
US
2 件公开
Hexahydro-pyrazino-pyridino-indole dione, and its synthesis and use
CN 1743329 A
申请人: CAPTIAL MEDICAL UNIV
优先权: 2004
CN
Hexahydro-pyrazino-pyridino-indole, and its systhesis and use
CN 1743328 A
申请人: CAPITAL MEDICAL UNIV
优先权: 2004
CN
3-ene-8-ethyl-2,7,12,15,18-pentamethyl-13-carboxylic acid-17-propionic acid amino acid amide, its synthetic method and light power therapeutic medicine
CN 1944433 A
申请人: GEN HOSPITAL PLA
优先权: 2006
CN
Ddc Compositions
US 2008318986 A1
申请人: SCHIFFMAN RHETT M
优先权: 2006
US
双载药插层水滑石纳米粒的制备方法及应用
CN 110354277 B
申请人: 沈阳药科大学
优先权: 2019
CN
Application of schisantherin A in preparation of medicine for treating cholestatic liver disease
CN 115381814 A
申请人: SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV TCM
优先权: 2022
CN
High-crystallinity allocholic acid and application of high-crystallinity allocholic acid in preparation of medicine for preventing and treating cholestatic liver disease
CN 116554252 A
申请人: UNIV SOUTH CHINA TECH
优先权: 2023
CN
Application of L-serine in prevention and/or treatment of cholestatic liver disease
CN 121570450 A
申请人: UNIV CHONGQING MEDICAL
优先权: 2026
CN
基于胆酸-TGR5通路构建抑制型受训免疫巨噬细胞模型的方法
CN 122588003 A
申请人: 徐州医科大学
优先权: 2026
CN
药物
反馈